Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.58 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.58 |
| ▸ | PDE5A | O76074 | 17/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174664 | 0.88 | GUCY1A1 (0.59) | GUCY1A1GUCY1B1PDE5A | |
| Hydrochloric Acid SCHEMBL15732830 | 0.87 | GUCY1A1 (0.58) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL174875 | 0.85 | PDE5A (0.59) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL26637716 | 0.84 | PDE5A (0.59) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL14864525 | 0.83 | PDE5A (0.59) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL24114778 | 0.82 | PDE5A (0.57) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL9913933 | 0.81 | PDE5A (0.82) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL174909 | 0.81 | PDE5A (0.55) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL25975252 | 0.81 | PDE5A (0.53) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL19934091 | 0.81 | PDE5A (0.57) | GUCY1A1GUCY1B1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | CHIA TAL TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | CHIA TAL TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257398-A1 | PYRIMIDINE-BASED TRICYCLIC COMPOUND AND USE THEREOF | TYMP, TYMS, DPYD | GUCY1A1 2940/4885GUCY1B1 2239/4885PDE5A 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.